Health and Fitness Health and Fitness
Tue, December 13, 2011
[ Tue, Dec 13th 2011 ] - Market Wire
Risultati finali della fase II analizzano l'effet .. pazienti con leucemia linfocitica cronica refrat
[ Tue, Dec 13th 2011 ] - Market Wire
Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound
[ Tue, Dec 13th 2011 ] - Market Wire
Nordion Reports Strong Fiscal 2011 Financial Results;; Provides Fiscal 2012 Outlook
[ Tue, Dec 13th 2011 ] - Market Wire
Rigrodsky & Long, P.A. Files Securities Fraud Cla .. Action Lawsuit Against The Cooper Companies, Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
Harwood Feffer LLP Announces Investigation of Synovis Life Technologies, Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
Fase 3 onderzoek ter evaluatie van REVLIMID bij p .. o smeulend multipel myeloom gepresenteerd bij ASH
[ Tue, Dec 13th 2011 ] - Market Wire
Fase III dello studio, presentata all'ASH, consid .. alta probabilit di sviluppare mieloma multiplo in
[ Tue, Dec 13th 2011 ] - Market Wire
Teva to Host 2012 Business Outlook Conference Call
[ Tue, Dec 13th 2011 ] - Market Wire
Sun Healthcare Group, Inc. Completes Amendment to Its Senior Secured Credit Facility
[ Tue, Dec 13th 2011 ] - Market Wire
West Announces First Quarter 2012 Dividend
[ Tue, Dec 13th 2011 ] - Market Wire
Electrochem Announces Agreement to Acquire Micro Power Electronics
[ Tue, Dec 13th 2011 ] - Market Wire
MannKind Resolves All Claims in Arbitration with Former Employee
[ Tue, Dec 13th 2011 ] - Market Wire
Amgen Presents Final Results from the Largest Pha .. ng the Safety and Efficacy of Nplate (Romiplostim
[ Tue, Dec 13th 2011 ] - Market Wire
WellPoint Donates $50,000 to Feeding America -- P .. .3 Million Associate Giving Campaign Contribution
[ Tue, Dec 13th 2011 ] - Market Wire
Kendall Law Group Investigates Synovis Life Technologies Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
REVLIMID gevalueerd in combinatie met rituximab a .. patinten met onbehandelde chronische lymfocytair
[ Tue, Dec 13th 2011 ] - Market Wire
Trattamento combinato REVLIMID-Rituximab potenzia .. diagnosi affetti da Leucemia linfocitica cronica
[ Tue, Dec 13th 2011 ] - Market Wire
Final Phase II Data Evaluating REVLIMID and Ritux .. lapsed or Refractory Chronic Lymphocytic Leukemia
[ Tue, Dec 13th 2011 ] - Market Wire
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Synovis Life Technologies, Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
Phase III Study Evaluating REVLIMID in Patients w .. Risk Smoldering Multiple Myeloma Presented at ASH
[ Tue, Dec 13th 2011 ] - Market Wire
The Briscoe Law Firm and Powers Taylor, LLP Inves .. ife Technologies, Inc. Concerning the Sale of SYN
[ Tue, Dec 13th 2011 ] - Market Wire
REVLIMID Evaluated in Combination with Rituximab .. Patients with Treatment-Naive Chronic Lymphocytic
[ Tue, Dec 13th 2011 ] - Market Wire
ICU Medical's Tego Needlefree Connector Proves Mo .. ve Than Traditional Central Venous Catheter Locks
[ Tue, Dec 13th 2011 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Announces I .. reaches of Fiduciary Duty by the Board of Synovis
[ Tue, Dec 13th 2011 ] - Market Wire
Pharmacyclics Announces Updated Results for BTK I .. eatment of Relapsed or Refractory Chronic Lymphoc
[ Tue, Dec 13th 2011 ] - Market Wire
Daxor Announces That the VA Medical Center in Was .. gton, D.C. Acquires BVA-100 Blood Volume Analyzer
[ Tue, Dec 13th 2011 ] - Market Wire
Rigrodsky & Long, P.A. Announces Investigation of .. ologies, Inc.as Sale to Baxter International Inc.
[ Tue, Dec 13th 2011 ] - Market Wire
Healthways to Update 2011 Financial Guidance after Market Close on December 20
[ Tue, Dec 13th 2011 ] - Market Wire
Seattle Genetics and Millennium Report Data from .. Brentuximab Vedotin) in Front-line Hodgkin Lympho
[ Tue, Dec 13th 2011 ] - Market Wire
U.S. Physical Therapy to Present at the Oppenheimer 22nd Annual Healthcare Conference

U.S. Physical Therapy to Present at the Oppenheimer 22nd Annual Healthcare Conference


Published on 2011-12-13 07:41:37 - Market Wire
  Print publication without navigation


HOUSTON--([ ])--U.S. Physical Therapy, Inc. (NASDAQ:USPH), a national operator of physical and occupational therapy outpatient clinics (the aCompanya), today announced that its Chief Financial Officer, Larry McAfee, will present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011. The presentation will cover an overview of the Company. The conference is being held at the Waldorf Astoria Hotel in New York.

A copy of the presentation is posted on the Companyas website at [ www.usph.com ].

About U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. operates 416 clinics in 42 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, non-surgical treatment of osteoarthritis, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages physical therapy facilities for third parties, including hospitals and physician groups.

More information about U.S. Physical Therapy, Inc. is available at [ www.usph.com ]. The information included on that website is not incorporated into this press release.

Contributing Sources